Abiopharma

IQVIA - IQVIA Named to the Fortune® World’sMost Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year

Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

agilon health - agilon health Sets Date to Report Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Perimeter Solutions Completes Acquisition of MMT

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Intuitive Announces Fourth Quarter Earnings

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Amlan® International Announces Promotion of Dr. Robin Jarquin to Vice President of Sales – Latin America

Amlan® International anuncia el nombramiento del Dr. Robin Jarquin como Vice Presidente Comercial para Latinoamérica

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

Amlan® International Anuncia Promoção do Dr. Robin Jarquin para Vice-Presidente de Vendas – América Latina

I-Mab (IMAB) Files Form 6-K